藥品參考
Concizumab
Concizumab is a medicine in the class miscellaneous. It is used for hemophilia a.
- 藥物類別: Miscellaneous
- 用途: hemophilia a
最後更新 來源: US FDA label
僅供醫療專業人員參考。本頁為簡要摘要，並非醫療建議，亦不能取代官方仿單或臨床判斷。開立處方或調劑前請務必核實。
本頁的臨床內容僅提供英文版。
重點資訊
- 藥物類別
- Miscellaneous
- ATC 代碼
- B02BX10
- 常見劑型
- 注射劑
- 已知交互作用
- 2 (嚴重: 2)
- 商品名
- 2
- 國家與市場
- 2
用途
作用方式
Monoclonal antibody antagonist of tissue factor pathway inhibitor (TFPI). Inhibiting TFPI enhances FXa production during initiation of coagulation, improving thrombin generation and clot formation regardless of inhibitor status.
成人常用劑量（仿單摘要）
Routine prophylaxis in hemophilia A or B: Day 1 loading dose 1 mg/kg subcutaneously; Day 2 onward 0.2 mg/kg once daily until the maintenance dose is individualized.
懷孕與哺乳
- 懷孕
- Unsafe May cause fetal harm based on mechanism of action; use only if benefit outweighs risk. Highly effective contraception advised during and for 7 weeks after treatment.
- 哺乳
- Unknown No information on presence in milk. Risk to infant cannot be excluded in the first days after birth; afterwards it could be used if clinically needed.
已通報的副作用
- Injection site reactions
- Headache
- Urticaria
禁忌症
- History of known serious hypersensitivity to Alhemo or its components or inactive ingredients.
哪些人需要特別留意
- Thromboembolic events (venous and arterial) occurred in 1.9% of patients; monitor and discontinue if suspected.
- Hypersensitivity reactions including anaphylaxis can occur; discontinue if severe.
- Increases fibrin D-dimer and prothrombin fragment 1.2; these biomarkers may not be reliable for suspected thrombosis.
請告知藥師或醫師您是否懷孕或哺乳、是否患有腎臟或肝臟疾病、是否有過敏，以及您正在使用的所有其他藥物或保健品。
重要交互作用 (2)
- Concizumab + Factor ix Major
- Concizumab + Factor viii Major
同類別的其他藥品
常見問題
What is Concizumab used for?
Concizumab is a medicine in the class miscellaneous. It is used for Hemophilia a, Hemophilia b.
What side effects have been reported with Concizumab?
Injection site reactions, Headache, Urticaria.
Can Concizumab be taken in pregnancy or while breastfeeding?
Pregnancy: Unsafe. May cause fetal harm based on mechanism of action; use only if benefit outweighs risk. Highly effective contraception advised during and for 7 weeks after treatment. Breastfeeding: Unknown. No information on presence in milk. Risk to infant cannot be excluded in the first days after birth; afterwards it could be used if clinically needed.
What does Concizumab interact with?
MediHelp lists 2 known interactions for Concizumab. Major: 2. The most serious include Factor ix, Factor viii.
在 MediHelp App 中取得完整藥品專論、劑量資訊與交互作用檢查
在 MediHelp App 中開啟完整參考資料、檢查多種藥物間的交互作用，並使用劑量工具。
